Anupam Rasayan India (ANURAS) Panoramica del titolo
Anupam Rasayan India Ltd si occupa della sintesi e della produzione di specialità chimiche in India, Europa, Giappone, Singapore, Cina, Nord America e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 1/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per ANURAS dai nostri controlli di rischio.
ANURAS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Anupam Rasayan India Ltd
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹1,207.80 |
| Massimo di 52 settimane | ₹1,415.00 |
| Minimo di 52 settimane | ₹1,045.20 |
| Beta | 0.12 |
| Variazione di 1 mese | -5.17% |
| Variazione a 3 mesi | -10.12% |
| Variazione di 1 anno | 6.26% |
| Variazione a 3 anni | 29.85% |
| Variazione a 5 anni | 69.54% |
| Variazione dall'IPO | 129.27% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 21
ANURAS: New Debt Plan Will Pressure Sentiment Despite Long-Term Supply Potential
Analysts have raised their price target for Anupam Rasayan India from ₹1,065 to ₹1,143, citing updated valuation work that reflects a slightly lower discount rate and a revised future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News Anupam Rasayan India signed a non-binding Letter of Intent with BASQUEVOLT, a European solid-state lithium battery developer based in Spain, to explore supplying a specialty chemical product for up to 10 years, with potential cumulative revenue of US$300 million, subject to product development and a definitive supply agreement.Aggiornamento narrativa • Jul 07
ANURAS: New Credit Issuance Will Pressure Sentiment Despite Recent Platform Milestone
Analysts have lifted their price target for Anupam Rasayan India from ₹976.43 to ₹1,065.00, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News Anupam Rasayan India announced it has become the first company globally to commercialise ETFA (Ethyl trifluoroacetate) using a proprietary continuous flow chemistry platform.
Aggiornamento narrativa • Jun 23
ANURAS: Planned Debt Expansion Will Sustain An Unfavorable Risk Profile
Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹640.00 to ₹800.00, reflecting updated assumptions on revenue growth, profit margins and future P/E multiples. What’s in the News for Anupam Rasayan India Anupam Rasayan India announced the commercialisation of ETFA (Ethyl trifluoroacetate) using its proprietary continuous flow chemistry platform, positioning the company as the first globally to produce ETFA at commercial scale using flow technology.
Aggiornamento narrativa • Jun 08
ANURAS: Upcoming Debt Raise And Subsidiary Guarantees Will Support Future Upside
Analysts have inched up their fair value estimate for Anupam Rasayan India from ₹1,667.80 to ₹1,680.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The board has scheduled a meeting on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to recommend a final dividend for FY 2025-26.Recent updates
Aggiornamento narrativa • Jul 21
ANURAS: New Debt Plan Will Pressure Sentiment Despite Long-Term Supply Potential
Analysts have raised their price target for Anupam Rasayan India from ₹1,065 to ₹1,143, citing updated valuation work that reflects a slightly lower discount rate and a revised future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News Anupam Rasayan India signed a non-binding Letter of Intent with BASQUEVOLT, a European solid-state lithium battery developer based in Spain, to explore supplying a specialty chemical product for up to 10 years, with potential cumulative revenue of US$300 million, subject to product development and a definitive supply agreement.Aggiornamento narrativa • Jul 07
ANURAS: New Credit Issuance Will Pressure Sentiment Despite Recent Platform Milestone
Analysts have lifted their price target for Anupam Rasayan India from ₹976.43 to ₹1,065.00, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News Anupam Rasayan India announced it has become the first company globally to commercialise ETFA (Ethyl trifluoroacetate) using a proprietary continuous flow chemistry platform.Aggiornamento narrativa • Jun 23
ANURAS: Planned Debt Expansion Will Sustain An Unfavorable Risk Profile
Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹640.00 to ₹800.00, reflecting updated assumptions on revenue growth, profit margins and future P/E multiples. What’s in the News for Anupam Rasayan India Anupam Rasayan India announced the commercialisation of ETFA (Ethyl trifluoroacetate) using its proprietary continuous flow chemistry platform, positioning the company as the first globally to produce ETFA at commercial scale using flow technology.Aggiornamento narrativa • Jun 08
ANURAS: Upcoming Debt Raise And Subsidiary Guarantees Will Support Future Upside
Analysts have inched up their fair value estimate for Anupam Rasayan India from ₹1,667.80 to ₹1,680.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The board has scheduled a meeting on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to recommend a final dividend for FY 2025-26.Aggiornamento narrativa • May 25
ANURAS: Planned Debt Issuance Will Sustain An Unfavorable Risk Profile
Analysts have lifted their price target on Anupam Rasayan India from ₹625 to ₹640, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of this change. What's in the News A board meeting is scheduled for May 23, 2026 at 12:45 IST to review and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend on equity shares for FY 2025-26 (company filing).Aggiornamento narrativa • May 06
ANURAS: Upcoming Overseas Subsidiary Guarantees Will Support Future Upside
Analysts have slightly adjusted their price target for Anupam Rasayan India to around ₹1,668, reflecting updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News A special shareholders meeting is scheduled for May 7, 2026 via postal ballot to seek approval for guarantees and security interests linked to the credit facility of wholly owned subsidiary Doriath S.à.r.l. This may include security over the shares and assets of Doriath S.à.r.l and Jayhawk Fine Chemicals Corporation (company filing).Aggiornamento narrativa • Apr 21
ANURAS: Upcoming Board Actions On Overseas Units Will Support Future Upside
Analysts have kept their fair value estimate for Anupam Rasayan India broadly unchanged at about ₹1,668, citing slight tweaks to the discount rate, revenue growth, profit margin and future P/E inputs that together support this stable price target view. What's in the News A board meeting is scheduled on Feb 12, 2026, to consider 12,000 shares of Doriath S.à r.l.; 1,800 shares of Batam S.à r.l. representing a 15% equity stake; potential credit facility transactions; an ECB facility agreement with Axis Bank Limited, IBU GIFT City; appointment of Axis Trustee Services Limited as security trustee; and other matters (Key Developments).Aggiornamento narrativa • Apr 07
ANURAS: Overseas Subsidiary Financing Structure Will Support Future Upside Potential
Analysts have nudged their fair value estimate for Anupam Rasayan India to about ₹1,668. This change is linked to updated assumptions on discount rate, revenue growth, profit margin and future P/E.Aggiornamento narrativa • Mar 23
ANURAS: Upcoming Credit Facilities And Subsidiary Transactions Will Pressure Sentiment Through 2026
The analyst price target for Anupam Rasayan India has been revised from ₹922 to ₹976, with analysts citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples to support the new view. What's in the News Board meeting on Feb 12, 2026 to review 12,000 shares of Doriath S.à r.l., a wholly owned subsidiary, and 1,800 shares of Batam S.à r.l. representing a 15% equity stake in Batam (Key Developments).Aggiornamento narrativa • Mar 09
ANURAS: Overseas Acquisitions And Expanded Borrowing Capacity Will Drive Future Upside
Analysts have nudged their fair value estimate for Anupam Rasayan India to about ₹1,668 per share, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and future P/E that leave the overall valuation picture broadly unchanged. What's in the News A board meeting is scheduled for Feb 12, 2026 to review the potential acquisition of 12,000 shares of Doriath S.à r.l. and 1,800 shares of Batam S.à r.l. representing 15% equity in Batam, and to consider new credit facilities and related security arrangements with Axis Bank Limited and Axis Trustee Services Limited (Key Developments).Aggiornamento narrativa • Feb 23
ANURAS: Future Overseas Acquisitions And Borrowing Headroom Will Redefine Upside Potential
Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹1,305.00 to about ₹1,667.80, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Board meeting on Feb 12, 2026 to review acquisition of 12,000 shares of Doriath S.à r.l., a wholly owned subsidiary, and 1,800 shares in Batam S.à r.l. representing a 15% equity stake, along with related credit facility arrangements, including an ESCB Facility with Axis Bank Limited, IBU GIFT City, and appointment of Axis Trustee Services Limited as security trustee under an ECB Facility (company board notice).Aggiornamento narrativa • Feb 08
ANURAS: Planned Acquisition And Higher Leverage Will Sustain An Unfavorable Risk Profile
Analysts have kept their fair value estimate for Anupam Rasayan India steady at ₹625.00 per share, highlighting slightly adjusted assumptions around discount rate, revenue growth and profit margin as the key drivers behind the unchanged target. What's in the News A board meeting is scheduled for Feb 14, 2026 to consider and approve unaudited financial results for the quarter and nine months ended Dec 31, 2025, providing the next formal update on recent financial performance (company filing).Aggiornamento narrativa • Jan 25
ANURAS: Planned Acquisition And Higher Leverage Will Drive An Unfavorable Risk Profile
Analysts have raised their price target on Anupam Rasayan India from ₹520 to ₹625, citing updated assumptions for profit margins, growth and P/E that they consider better reflect the stock’s risk profile and return outlook. What's in the News Board meeting on Dec 09, 2025 to consider and approve the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, along with a related loan receivable from CABB GmbH, and the execution of a Sale and Purchase Agreement (company filing).Articolo di analisi • Jan 21
Investors Met With Slowing Returns on Capital At Anupam Rasayan India (NSE:ANURAS)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Aggiornamento narrativa • Jan 08
ANURAS: Planned Acquisition And Higher Leverage Will Pressure Sentiment Through 2026
Analysts have lifted their fair value estimate for Anupam Rasayan India from ₹905 to about ₹922, citing updated assumptions for the discount rate, long term revenue growth, profit margins and the future P/E multiple. What's in the News The board will meet on Dec 09, 2025 to consider and approve the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, along with a related loan receivable from CABB GmbH, and to authorize a Sale and Purchase Agreement and postal ballot notice.Articolo di analisi • Dec 16
Is Anupam Rasayan India (NSE:ANURAS) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Aggiornamento narrativa • Dec 14
ANURAS: Acquisition And Auditor Shift Will Pressure Sentiment Through 2026
Analysts have nudged their price target for Anupam Rasayan India slightly higher to ₹905.0 from ₹905, citing marginal improvements in the discount rate and long term profitability assumptions while keeping growth expectations largely intact. What's in the News Board meeting scheduled for December 09, 2025 to consider the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, along with related loan receivable and Sale and Purchase Agreement approvals (company filing) Special shareholders meeting via postal ballot on January 09, 2026 to seek investor approval for the proposed acquisition and related resolutions (company filing) Special shareholders meeting via postal ballot on December 22, 2025, with voting conducted through remote e-voting (company filing) Board meeting held on November 21, 2025 to approve the postal ballot notice, set the cut-off date, define the e-voting window, and appoint a scrutinizer for the postal ballot process (company filing) Board meeting on October 17, 2025 to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Shareholders at the September 26, 2025 AGM approved the appointment of Natvarlal Vepari and Co., Chartered Accountants, Surat, as the company’s new statutory auditor (company filing) Valuation Changes Fair Value: Maintained effectively flat at ₹905.0, reflecting no material change in the intrinsic value estimate.Aggiornamento narrativa • Nov 30
ANURAS: Auditor Transition And Board Actions Will Pressure Sentiment Through 2025
Analysts have maintained their fair value estimate for Anupam Rasayan India at ₹905.00, citing stable forecast assumptions, even with minor adjustments in financial metrics. What's in the News The company scheduled a Special/Extraordinary Shareholders Meeting on December 22, 2025, to be conducted via postal ballot in India.Articolo di analisi • Nov 20
Anupam Rasayan India Ltd (NSE:ANURAS) Investors Are Less Pessimistic Than Expected
When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...Aggiornamento narrativa • Nov 16
ANURAS: Net Profit Margin Will Weaken Amid Management And Auditor Changes
Analysts have slightly reduced their price target for Anupam Rasayan India to ₹905.00 per share, citing modest adjustments in profit margin expectations and valuation assumptions. What's in the News A board meeting is scheduled for October 17, 2025 to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (Company Filing).Aggiornamento narrativa • Nov 01
ANURAS: Slowing Revenue Expansion Will Pressure Margins Despite Profit Recovery
Analysts have raised their price target for Anupam Rasayan India from ₹884.29 to ₹909.29, citing improved profit margin expectations even though projected revenue growth is expected to moderate. What's in the News The board meeting is scheduled for October 17, 2025, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments).Aggiornamento narrativa • Oct 18
Growing Contract Wins And Tightening Margins Will Shape Future Prospects
Analysts have revised their price target for Anupam Rasayan India upward from ₹838 to ₹884. They cited slight adjustments in the discount rate and an upward recalibration of fair value in their latest models.Articolo di analisi • Oct 02
Returns On Capital At Anupam Rasayan India (NSE:ANURAS) Have Hit The Brakes
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Aggiornamento narrativa • Aug 22
Expanding Pharma And Polymer Segments To Drive Future Success
Despite a notable reduction in consensus revenue growth forecasts, expectations for Anupam Rasayan India's earnings multiple have increased, resulting in a higher analyst price target now at ₹837.86. What's in the News Board meeting scheduled to consider and approve unaudited Q1 FY26 financial results.Articolo di analisi • May 28
Anupam Rasayan India Ltd Just Missed EPS By 7.1%: Here's What Analysts Think Will Happen Next
Investors in Anupam Rasayan India Ltd ( NSE:ANURAS ) had a good week, as its shares rose 3.0% to close at ₹991...Articolo di analisi • Apr 08
Anupam Rasayan India Ltd (NSE:ANURAS) Not Lagging Industry On Growth Or Pricing
When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...
Nuova narrativa • Mar 11
Expanding Pharma And Polymer Segments To Drive Future Success
Pharma and Polymer growth, energy cost cuts, and a robust pipeline with new molecules will drive future revenue growth and improve net margins.Articolo di analisi • Nov 25
Anupam Rasayan India's (NSE:ANURAS) Problems Go Beyond Weak Profit
A lackluster earnings announcement from Anupam Rasayan India Ltd ( NSE:ANURAS ) last week didn't sink the stock price...Articolo di analisi • Nov 18
Earnings Report: Anupam Rasayan India Ltd Missed Revenue Estimates By 9.2%
The second-quarter results for Anupam Rasayan India Ltd ( NSE:ANURAS ) were released last week, making it a good time...Articolo di analisi • Nov 02
Anupam Rasayan India (NSE:ANURAS) Hasn't Managed To Accelerate Its Returns
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Articolo di analisi • Aug 24
Time To Worry? Analysts Just Downgraded Their Anupam Rasayan India Ltd (NSE:ANURAS) Outlook
Today is shaping up negative for Anupam Rasayan India Ltd ( NSE:ANURAS ) shareholders, with the analysts delivering a...Articolo di analisi • Aug 17
Anupam Rasayan India Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
As you might know, Anupam Rasayan India Ltd ( NSE:ANURAS ) last week released its latest quarterly, and things did not...Articolo di analisi • May 26
Anupam Rasayan India's (NSE:ANURAS) Shareholders Have More To Worry About Than Only Soft Earnings
A lackluster earnings announcement from Anupam Rasayan India Limited ( NSE:ANURAS ) last week didn't sink the stock...Articolo di analisi • May 22
Analyst Estimates: Here's What Brokers Think Of Anupam Rasayan India Limited (NSE:ANURAS) After Its Full-Year Report
Last week saw the newest annual earnings release from Anupam Rasayan India Limited ( NSE:ANURAS ), an important...Articolo di analisi • Dec 30
What You Can Learn From Anupam Rasayan India Ltd's (NSE:ANURAS) P/E
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 29x, you may consider Anupam...Articolo di analisi • Nov 03
Anupam Rasayan India (NSE:ANURAS) Might Have The Makings Of A Multi-Bagger
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Articolo di analisi • Jul 13
Is Now The Time To Put Anupam Rasayan India (NSE:ANURAS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • Jun 24
Anupam Rasayan India's (NSE:ANURAS) Returns On Capital Are Heading Higher
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Rendimenti per gli azionisti
| ANURAS | IN Chemicals | IN Mercato | |
|---|---|---|---|
| 7D | -3.3% | 1.1% | 2.0% |
| 1Y | 6.3% | -2.0% | 3.6% |
Ritorno vs Industria: ANURAS ha superato il Indian Chemicals che ha restituito -2 % nell'ultimo anno.
Rendimento vs Mercato: ANURAS ha superato il mercato Indian che ha restituito 3.6 % nell'ultimo anno.
Volatilità dei prezzi
| ANURAS volatility | |
|---|---|
| ANURAS Average Weekly Movement | 2.6% |
| Chemicals Industry Average Movement | 6.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
Prezzo delle azioni stabile: ANURAS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 3% ) di ANURAS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1984 | 2,606 | Gopal Agrawal | www.anupamrasayan.com |
Anupam Rasayan India Ltd si occupa della sintesi e della produzione di specialità chimiche in India, Europa, Giappone, Singapore, Cina, Nord America e a livello internazionale. Opera attraverso due segmenti: Prodotti chimici speciali per le scienze della vita e Altri prodotti chimici speciali. L'azienda offre specialità chimiche per le scienze della vita, come intermedi e principi attivi agricoli per l'industria agrochimica; intermedi e ingredienti per la protezione antibatterica e ultravioletta per l'industria della cura personale; intermedi e materie prime chiave per i principi attivi farmaceutici.
Anupam Rasayan India Ltd Riepilogo dei fondamenti
| ANURAS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹137.51b |
| Utili (TTM) | ₹1.70b |
| Ricavi(TTM) | ₹23.65b |
80.8x
Rapporto P/E5.8x
Rapporto P/SANURAS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ANURAS Conto economico (TTM) | |
|---|---|
| Ricavi | ₹23.65b |
| Costo del fatturato | ₹13.23b |
| Profitto lordo | ₹10.42b |
| Altre spese | ₹8.72b |
| Utili | ₹1.70b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 14.94 |
| Margine lordo | 44.06% |
| Margine di profitto netto | 7.19% |
| Rapporto debito/patrimonio netto | 39.2% |
Come si è comportato ANURAS nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.1%
Rendimento attuale del dividendo10%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/01 20:09 |
| Prezzo dell'azione a fine giornata | 2026/07/31 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Anupam Rasayan India Ltd è coperta da 10 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Satish Kumar | CGS International |
| Dane Leone | CGS International |